Is It Time to Reconsider Rituximab Dosing Regimens for Pemphigus Vulgaris?
Abstract
1. Introduction
2. Case Presentation
3. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Malik, A.M.; Tupchong, S.; Huang, S.; Are, A.; Hsu, S.; Motaparthi, K. An Updated Review of Pemphigus Diseases. Medicina 2021, 57, 1080. [Google Scholar] [CrossRef] [PubMed]
- Joly, P.; Horvath, B.; Patsatsi, A.; Uzun SO NE, R.; Bech, R.; Beissert, S.; Bergman, R.; Bernard, P.; Borradori, L.; Caproni, M.; et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J. Eur. Acad. Dermatol. Venereol. 2020, 34, 1900–1913. [Google Scholar] [CrossRef] [PubMed]
- Khandelwal, K.; Jajoo, V.; Bajpai, K.; Madke, B.; Prasad, R.; Wanjari, M.B.; Munjewar, P.K.; Taksande, A.B. Rituximab in Pemphigus Vulgaris: A Review of Monoclonal Antibody Therapy in Dermatology. Cureus 2023, 15, e40734. [Google Scholar] [CrossRef] [PubMed]
- Abulayha, A.; Bredan, A.; El Enshasy, H.; Daniels, I. Rituximab: Modes of action, remaining dispute and future perspective. Future Oncol. 2014, 10, 2481–2492. [Google Scholar] [CrossRef] [PubMed]
- Eming, R.; Nagel, A.; Wolff-Franke, S.; Podstawa, E.; Debus, D.; Hertl, M. Rituximab exerts a dual effect in pemphigus vulgaris. J. Investig. Dermatol. 2008, 128, 2850–2858. [Google Scholar] [CrossRef] [PubMed]
- Schoergenhofer, C.; Schwameis, M.; Firbas, C.; Bartko, J.; Derhaschnig, U.; Mader, R.M.; Plaßmann, R.S.; Jilma-Stohlawetz, P.; Desai, K.; Misra, P.; et al. Single, very low rituximab doses in healthy volunteers—A pilot and a randomized trial: Implications for dosing and biosimilarity testing. Sci. Rep. 2018, 8, 124. [Google Scholar] [CrossRef] [PubMed]
- Ciolfi, C.; Sernicola, A.; Alaibac, M. Role of Rituximab in the Treatment of Pemphigus Vulgaris: Patient Selection and Acceptability. Patient Prefer. Adherence 2022, 16, 3035–3043. [Google Scholar] [CrossRef] [PubMed]
- Genentech. Rituxan® (rituximab [Oncology]). Information for Healthcare Providers. Available online: https://www.gene.com/medical-professionals/medicines/rituxan-oncology (accessed on 11 September 2023).
- EMA MabThera. European Medicines Agency; 17 September 2018. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/mabthera (accessed on 11 September 2023).
- Wang, H.H.; Liu, C.W.; Li, Y.C.; Huang, Y.C. Efficacy of rituximab for pemphigus: A systematic review and meta-analysis of different regimens. Acta Derm. Venereol. 2015, 95, 928–932. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.H.; Kim, Y.H.; Kim, M.R.; Kim, S.C. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: A retrospective study of 27 patients. Br. J. Dermatol. 2011, 165, 646–651. [Google Scholar] [CrossRef] [PubMed]
- Kanwar, A.J.; Vinay, K.; Sawatkar, G.U.; Dogra, S.; Minz, R.W.; Shear, N.H.; Koga, H.; Ishii, N.; Hashimoto, T. Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: A randomized, comparative, observer-blinded study. Br. J. Dermatol. 2014, 170, 1341–1349. [Google Scholar] [CrossRef] [PubMed]
- Cho, H.H.; Jin, S.P.; Chung, J.H. Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities. J. Eur. Acad. Dermatol. Venereol. 2014, 28, 186–191. [Google Scholar] [CrossRef] [PubMed]
- Russo, I.; Miotto, S.; Saponeri, A.; Alaibac, M. Ultra-low dose rituximab for refractory pemghigus vulgaris: A pilot study. Expert Opin. Biol. Ther. 2020, 20, 673–678. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ciolfi, C.; Tartaglia, J.; Alaibac, M. Is It Time to Reconsider Rituximab Dosing Regimens for Pemphigus Vulgaris? Antibodies 2024, 13, 4. https://doi.org/10.3390/antib13010004
Ciolfi C, Tartaglia J, Alaibac M. Is It Time to Reconsider Rituximab Dosing Regimens for Pemphigus Vulgaris? Antibodies. 2024; 13(1):4. https://doi.org/10.3390/antib13010004
Chicago/Turabian StyleCiolfi, Christian, Jacopo Tartaglia, and Mauro Alaibac. 2024. "Is It Time to Reconsider Rituximab Dosing Regimens for Pemphigus Vulgaris?" Antibodies 13, no. 1: 4. https://doi.org/10.3390/antib13010004
APA StyleCiolfi, C., Tartaglia, J., & Alaibac, M. (2024). Is It Time to Reconsider Rituximab Dosing Regimens for Pemphigus Vulgaris? Antibodies, 13(1), 4. https://doi.org/10.3390/antib13010004